Caushi, Justina X.
Zhang, Jiajia
Ji, Zhicheng
Vaghasia, Ajay
Zhang, Boyang
Hsiue, Emily Han-Chung
Mog, Brian J. http://orcid.org/0000-0001-9988-7147
Hou, Wenpin http://orcid.org/0000-0003-0972-2192
Justesen, Sune
Blosser, Richard
Tam, Ada
Anagnostou, Valsamo http://orcid.org/0000-0001-9480-3047
Cottrell, Tricia R. http://orcid.org/0000-0003-2952-1830
Guo, Haidan
Chan, Hok Yee
Singh, Dipika
Thapa, Sampriti
Dykema, Arbor G.
Burman, Poromendro
Choudhury, Begum
Aparicio, Luis
Cheung, Laurene S.
Lanis, Mara
Belcaid, Zineb
El Asmar, Margueritta
Illei, Peter B.
Wang, Rulin
Meyers, Jennifer
Schuebel, Kornel
Gupta, Anuj
Skaist, Alyza
Wheelan, Sarah http://orcid.org/0000-0002-9002-0800
Naidoo, Jarushka
Marrone, Kristen A.
Brock, Malcolm
Ha, Jinny
Bush, Errol L.
Park, Bernard J.
Bott, Matthew
Jones, David R.
Reuss, Joshua E.
Velculescu, Victor E. http://orcid.org/0000-0003-1195-438X
Chaft, Jamie E. http://orcid.org/0000-0002-5838-9982
Kinzler, Kenneth W.
Zhou, Shibin http://orcid.org/0000-0003-1941-4425
Vogelstein, Bert
Taube, Janis M.
Hellmann, Matthew D.
Brahmer, Julie R.
Merghoub, Taha http://orcid.org/0000-0002-1518-5111
Forde, Patrick M.
Yegnasubramanian, Srinivasan http://orcid.org/0000-0003-0744-6606
Ji, Hongkai http://orcid.org/0000-0002-6480-0141
Pardoll, Drew M.
Smith, Kellie N. http://orcid.org/0000-0002-6295-8930
Article History
Received: 8 January 2021
Accepted: 18 June 2021
First Online: 21 July 2021
Change Date: 4 October 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-021-03893-6
Competing interests
: V.A. receives research funding from Bristol-Myers Squibb and Astra Zeneca. J.M.T. receives research funding from Bristol-Myers Squibb and serves a consulting/advisory role for Bristol-Myers Squibb, Merck, and Astra Zeneca. P.B.I. receives research funding from Bristol-Myers Squibb and Erbe Elektromedizin GmbH and serves a consulting/advisory role for AstraZeneca and Veran Medical Technologies. J.N. receives research funding from AstraZeneca, Bristol-Myers Squibb, and Merck, and serves a consulting/advisory role for AstraZeneca, Daiichi Sankyo, Bristol-Myers Squibb, Merck, and Roche/Genentech. K.A.M. is a consultant for Amgen and Astra Zeneca. D.R.J. is a consultant for More Health and AstraZeneca and a Steering Committee Member for Merck. B.J.P. is a consultant for AstraZeneca and Regeneron and has received honoraria from Intuitive Surgical. J.E.C. is a consultant for AstraZeneca, Genentech, Merck, Flame Bioscience, and Novartis. V.E.V. is a founder of Delfi Diagnostics and Personal Genome Diagnostics, serves on the Board of Directors and as a consultant for both organizations, and owns Delfi Diagnostics and Personal Genome Diagnostics stock, which are subject to certain restrictions under university policy. Additionally, Johns Hopkins University owns equity in Delfi Diagnostics and Personal Genome Diagnostics. V.E.V. is an advisor to Bristol-Myers Squibb, Genentech, Merck, and Takeda Pharmaceuticals. Within the last five years, V.E.V. has been an advisor to Daiichi Sankyo, Janssen Diagnostics, and Ignyta. M.D.H. receives research support from Bristol-Myers Squibb; has been a compensated consultant for Merck, Bristol-Myers Squibb, AstraZeneca, Genentech/Roche, Nektar, Syndax, Mirati, Shattuck Labs, Immunai, Blueprint Medicines, Achilles, Arcus, and Natera; received travel support/honoraria from AstraZeneca, Eli Lilly, and Bristol-Myers Squibb; has options from Shattuck Labs, Immunai, and Arcus; and has a patent filed by his institution related to the use of tumor mutation burden to predict response to immunotherapy (PCT/US2015/062208), which has received licensing fees from PGDx. The Johns Hopkins University is in the process of filing patent applications related to technologies described in this paper on which E.H.-C.H., B.V., K.W.K. and S.Z. are listed as inventors. B.V. and K.W.K. are founders of Thrive Earlier Detection. K.W.K. is a consultant to and was on the Board of Directors of Thrive Earlier Detection. B.V., K.W.K. and S.Z. own equity in Exact Sciences. B.V., K.W.K. and S.Z. are founders of, hold or may hold equity in, and serve or may serve as consultants to manaT Bio, and hold or may hold equity in manaT Holdings, LLC. B.V., K.W.K., and S.Z. are founders of, hold equity in, and serve as consultants to Personal Genome Diagnostics. S.Z. has a research agreement with BioMed Valley Discoveries. K.W.K. and B.V. are consultants to Sysmex, Eisai, and CAGE Pharma and hold equity in CAGE Pharma. B.V. is a consultant to and holds equity in Catalio. K.W.K., B.V. and S.Z. are consultants to and hold equity in NeoPhore. The companies named above, as well as other companies, have licensed previously described technologies related to the work from this lab at Johns Hopkins University. Licenses to these technologies are or will be associated with equity or royalty payments to the inventors as well as to Johns Hopkins University. T.M. is a cofounder and holds equity in IMVAQ Therapeutics, is a consultant for Immunos Therapeutics, ImmunoGenesis, and Pfizer, receives research funding from Bristol-Myers Squibb, Surface Oncology, Kyn Therapeutics, Infinity Pharmaceuticals, Inc., Peregrine Pharmaceuticals, Inc., Adaptive Biotechnologies, Leap Therapeutics, Inc., and Aprea, and holds patents on applications related to work on oncolytic viral therapy, alpha virus-based vaccines, neoantigen modeling, CD40, GITR, OX40, PD-1, and CTLA-4. J.R.B. serves an advisory/consulting role for Amgen, AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Eli Lilly, GlaxoSmithKline, Merck, Sanofi, and Regeneron, receives research funding from AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Merck, RAPT Therapeutics, Inc., and Revolution Medicines, and is on the Data and Safety Monitoring Board of GlaxoSmithKline, Janssen, and Sanofi. P.M.F. receives research support from AstraZeneca, Bristol-Myers Squibb, Novartis, and Kyowa, and has been a consultant for AstraZeneca, Amgen, Bristol-Myers Squibb, Daichii Sankyo, and Janssen and serves on a data safety and monitoring board for Polaris. S.Y. receives research funding from Bristol-Myers Squibb/Celgene, Janssen, and Cepheid, has served as a consultant for Cepheid, and owns founder’s equity in Astra Therapeutics and Digital Harmonic. K.N.S., D.M.P., B.V. and K.W.K. have filed for patent protection on the MANAFEST technology described herein (serial no. 16/341,862). K.N.S., D.M.P., J.E.C., B.V., E.H.-C.H. D.M.P., K.W.K. and S.Z. have filed for patent protection on the p53 R248L mutation-specific TCR described herein (serial no. 63/168,878). D.M.P. is a consultant for Compugen, Shattuck Labs, WindMIL, Tempest, Immunai, Bristol-Myers Squibb, Amgen, Janssen, Astellas, Rockspring Capital, Immunomic, Dracen and owns founder’s equity in manaT Holdings, LLC, WindMIL, Trex, Jounce, Anara, Tizona, Tieza, RAPT and receives research funding from Compugen, Bristol-Myers Squibb, and Anara. K.N.S. has received travel support/honoraria from Illumina, Inc., receives research funding from Bristol-Myers Squibb, Anara, and Astra Zeneca, and owns founder’s equity in manaT Holdings, LLC. The terms of all these arrangements are being managed by the respective institutions in accordance with their conflict-of-interest policies.